한글목차

Zanaflex(티자니딘)는 중추성 알파2 작용제입니다. 여러 질병에 대한 항경련제로 널리 사용되고 있습니다.

티자니딘은 이미다졸린 유도체로 중추에 작용하는 α2 수용체 작용제입니다. 척수 매개 뉴런에서 글루탐산, 아스파르트산과 같은 흥분성 아미노산의 방출을 억제합니다. 그 결과, 티자니딘은 운동 뉴런의 시냅스 전 억제를 강화합니다. 척수 폴리시냅스 경로에 대한 중요한 작용을 나타냅니다.

이러한 작용의 전반적인 효과는 척수 운동 뉴런의 촉진을 감소시키는 것입니다. 마찬가지로, α2 수용체를 통한 신경 세포 간 활동의 억제는 티자니딘의 항침습성 수용체 및 항경련성 효과의 근간을 이루는 것으로 보입니다. 경련 빈도와 크론병도 티자니딘에 의해 감소합니다.

또한 티자니딘은 α1 수용체에도 친화력을 보이지만 그 정도가 낮기 때문에 클로니딘과 구조적, 생화학적 유사성에도 불구하고 심혈관계에 대한 작용이 온화하고 일시적이라는 것을 설명할 수 있습니다.

앞으로 수년간 세계에서 광범위한 조사와 의료비 지출 증가로 인해 경련증 시장 시나리오가 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 자나플렉스의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 경련에 대한 다른 신흥 제품들은 자나플렉스에 치열한 시장 경쟁을 가져올 것으로 예상되며, 가까운 시일 내에 후발 주자들이 시장에 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

주요 7개국의 ZANAFLEX 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 경직에 대한 ZANAFLEX의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 ZANAFLEX 시장 평가

• 경직에 대한 ZANAFLEX의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국의 경직에 대한 ZANAFLEX의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"ZANAFLEX Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ZANAFLEX for spasticity in the seven major markets. A detailed picture of the ZANAFLEX for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ZANAFLEX for spasticity. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZANAFLEX market forecast analysis for spasticity in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in spasticity.

Drug Summary:

ZANAFLEX (tizanidine) is a centrally acting alpha-2 agonist. It is widely used as an anti-spastic agent for multiple medical conditions.

Mechanism of action

Tizanidine is an imidazoline derivative and a centrally acting alpha-2 receptor agonist. Tizanidine inhibits the release of excitatory amino acids like glutamate and aspartate from spinal interneurons. Consequently, tizanidine enhances the presynaptic inhibition of motor neurons. Tizanidine has significant action on spinal polysynaptic pathways.

The overall effect of these actions is to reduce the facilitation of spinal motor neurons. Similarly, alpha-2 receptor-mediated inhibition of inter-neuronal activity appears to underlie tizanidine's additional anti-nociceptive and anti-convulsant activities. Spasm frequency and clonus are also reduced by tizanidine.

Tizanidine also has an affinity for the alpha-1 receptors but to a lesser degree, which may explain its mild and transitory effect on the cardiovascular system compared to clonidine despite their structural and biochemical similarity.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ZANAFLEX description, mechanism of action, dosage and administration, research and development activities in spasticity.
• Elaborated details on ZANAFLEX regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZANAFLEX research and development activities in spasticity across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ZANAFLEX.
• The report contains forecasted sales of ZANAFLEX for spasticity till 2032.
• Comprehensive coverage of the late-stage emerging therapies for spasticity.
• The report also features the SWOT analysis with analyst views for ZANAFLEX in spasticity.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZANAFLEX Analytical Perspective by DelveInsight

In-depth ZANAFLEX Market Assessment

This report provides a detailed market assessment of ZANAFLEX for spasticity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

ZANAFLEX Clinical Assessment

The report provides the clinical trials information of ZANAFLEX for spasticity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for spasticity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZANAFLEX dominance.
• Other emerging products for spasticity are expected to give tough market competition to ZANAFLEX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZANAFLEX in spasticity.
• Our in-depth analysis of the forecasted sales data of ZANAFLEX from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZANAFLEX in spasticity.

Key Questions:

• What is the product type, route of administration and mechanism of action of ZANAFLEX?
• What is the clinical trial status of the study related to ZANAFLEX in spasticity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZANAFLEX development?
• What are the key designations that have been granted to ZANAFLEX for spasticity?
• What is the forecasted market scenario of ZANAFLEX for spasticity?
• What are the forecasted sales of ZANAFLEX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZANAFLEX for spasticity?
• Which are the late-stage emerging therapies under development for the treatment of spasticity?

Table of Contents

1. Report Introduction

2. ZANAFLEX Overview in Spasticity

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ZANAFLEX Market Assessment

• 5.1. Market Outlook of ZANAFLEX in Spasticity
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ZANAFLEX in the 7MM for Spasticity
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ZANAFLEX in the United States for Spasticity
  • 5.3.2. Market Size of ZANAFLEX in Germany for Spasticity
  • 5.3.3. Market Size of ZANAFLEX in France for Spasticity
  • 5.3.4. Market Size of ZANAFLEX in Italy for Spasticity
  • 5.3.5. Market Size of ZANAFLEX in Spain for Spasticity
  • 5.3.6. Market Size of ZANAFLEX in the United Kingdom for Spasticity
  • 5.3.7. Market Size of ZANAFLEX in Japan for Spasticity

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options